
ENC is supplied as pre-dosed oral capsules at 11.5mg, verified for identity and content before release.
| Form | Oral capsules — pre-dosed, no reconstitution |
| Purity | ≥99% (verified) |
| Storage | Cool and dry, sealed; protect from light |
| Batch | COA available on request |
ENC is supplied as pre-dosed oral capsules at 11.5mg, verified for identity and content before release.
Enclomiphene is the trans-isomer of clomiphene citrate, isolated from the mixture. Clomiphene as normally supplied is roughly 62% enclomiphene and 38% zuclomiphene — two isomers with meaningfully different behaviour, which is the entire reason for separating them.
Zuclomiphene is the more estrogenic isomer and has a half-life measured in weeks, so it accumulates with repeated administration. Enclomiphene is the anti-estrogenic isomer and clears far faster. Isolating it was intended to keep the pituitary-stimulating activity while removing the component responsible for estrogenic accumulation.
Supplied as pre-dosed capsules at 11.5mg for laboratory research use only. Not for human consumption.
Enclomiphene acts as an antagonist at estrogen receptors in the hypothalamus and pituitary. Because circulating estradiol normally exerts negative feedback on gonadotropin release, blocking that signal removes the brake — the pituitary reads the situation as low estrogen and increases output.
The measured consequence is increased luteinising hormone and follicle-stimulating hormone, and downstream of LH, increased endogenous testosterone production in the testes. The compound does not supply testosterone; it stimulates the axis to make more.
This upstream mechanism is the reason enclomiphene appears in the fertility literature. Exogenous testosterone suppresses LH and FSH through the same feedback loop and with it spermatogenesis. Studies have examined whether stimulating the axis raises testosterone while preserving sperm parameters, which testosterone replacement does not.
A distinct strand compares enclomiphene against unfractionated clomiphene, testing whether removing zuclomiphene changes the profile as intended — this is a pharmacological question about the separation itself rather than about the target.
Enclomiphene has been studied in human trials for secondary hypogonadism, so a clinical literature exists. It has not been approved by the FDA for that indication. It is supplied here as a research reference compound.
| State | Temperature | Practical shelf life |
|---|---|---|
| Sealed bottle, room temperature | 15–25 °C | To printed expiry |
| Sealed bottle, refrigerated | 2–8 °C | To printed expiry |
| Opened bottle, tightly closed | 15–25 °C | Months, if kept dry |
| Exposed to humidity | any | Degrades — discard |
Oral dosage forms are considerably more forgiving than lyophilized peptides. Capsules and tablets are stable at room temperature and require no cold chain, in transit or in storage.
Moisture is the real enemy rather than temperature. Keep the bottle tightly closed, leave the desiccant sachet in place, and avoid storing in a bathroom or anywhere humidity swings. Protect from direct light.
Every lot is tested by an independent laboratory before release. HPLC establishes purity as a percentage of total content, separating the target compound from synthesis by-products; mass spectrometry confirms molecular identity.
For an encapsulated product there is a second question a vial does not raise: content uniformity. A capsule can be the right compound at the right purity and still be filled inconsistently, so Enclomiphene is checked for fill weight consistency across the batch as well as for identity and purity.
The certificate of analysis references the lot number printed on your bottle label. Request it at sales@pepsdepot.com.
Peer-reviewed studies indexed in PubMed. Each links to the abstract and, where a free copy exists, to the full text. We link primary sources rather than summarising them second-hand.
Join the Peps Depot mailing list for high-demand restock alerts, subscriber-only offers, release updates and priority access — plus The Friday Brief, our weekly peptide research newsletter covering what actually moved that week. New compounds, new trial data, regulatory shifts.